

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.
Investor Presentation Deck
Tetra Investor Presentation


Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.
Investor Presentation Deck
Tetra Investor Presentation
Based on strong results in its pre-clinical animal study, CytoDyn files for Orphan Drug Designation for Triple-Negative Breast Cancer VANCOUVER, Washington, Feb 20, 2019 – CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized […]
VANCOUVER, British Columbia, April 09, 2019 (GLOBE NEWSWIRE) — The Yield Growth Corp. (CSE: BOSS) (OTC: BOSQF) (frankfurt:YG3) announces its subsidiary Urban Juve has received positive national media attention from two of Canada’s leading lifestyle magazines […]
NEW YORK, Nov. 18, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
